0001437749-23-007443.txt : 20230321 0001437749-23-007443.hdr.sgml : 20230321 20230321200642 ACCESSION NUMBER: 0001437749-23-007443 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230317 FILED AS OF DATE: 20230321 DATE AS OF CHANGE: 20230321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Floroiu Cezar Andrei CENTRAL INDEX KEY: 0001808794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 23751038 MAIL ADDRESS: STREET 1: C/O VAXART, INC. STREET 2: 385 OYSTER POINT BOULEVARD, SUITE 9A CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 4 1 rdgdoc.xml FORM 4 X0407 4 2023-03-17 0000072444 Vaxart, Inc. VXRT 0001808794 Floroiu Cezar Andrei C/O VAXART, INC. 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 1 President, Chief Exec Officer 0 Common Stock 2023-03-17 4 A 0 100000 0 A 185000 D Common Stock 2023-03-17 4 A 0 92735 0 A 277735 D Common Stock 2023-03-17 4 A 0 175000 0 A 452735 D Stock Option (right to buy) 0.78 2023-03-17 4 A 0 400000 0 A 2033-03-16 Common Stock 400000 400000 D Stock Option (right to buy) 0.78 2023-03-17 4 A 0 750000 0 A 2033-03-16 Common Stock 750000 750000 D Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. The shares subject to this stock option shall fully vest on December 8, 2023. Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. /s/ Andrei Floroiu 2023-03-21